Lates News
Immunovant (IMVT.US): The fourth quarter financial report for 2025 achieved revenue of $0, with the previous value also being $0. Earnings per share were -$0.64, compared to the previous value of -$0.52, and the expected value was -$0.72.
Latest
1 m ago